The imbalance between vasoconstrictors and vasodilators may play an important role in the pathogenesis of erectile dysfunction (ED). A total of 36 patients with ED, organogenic [diabetic (n ¼ 12) and nondiabetic (n ¼ 12)] and psychogenic (n ¼ 12) etiology, and 12 healthy adult men as controls were included. The levels of endothelin-1 (ET-1), growth hormone (GH), angiotensinconverting enzyme activity (ACE), nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) were determined in the flaccid penis cavernosal blood of patients and in cubital blood of patients and controls. In psychogenic ED, systemic ACE activity was elevated compared to controls (Po0.05). In diabetic and nondiabetic ED patients, systemic levels of ET-1 (Po0.0001 for both) and ACE activity (Po0.01 and o0.05) were higher while GH (Po0.0001 and o0.001), NO (Po0.0001 for both) and cGMP (Po0.01 for both) levels were lower compared to controls. In diabetic patients, systemic and cavernosal ET-1 levels (Po0.0001 for both) and cavernosal ACE activity levels (Po0.05) were significantly elevated while systemic and cavernosal NO (Po0.0001 for both) and GH (o0.001 and o0.05) levels were declined compared to psychogenic. In nondiabetic patients, systemic and cavernosal ET-1 levels (Po0.0001 for both) were significantly elevated while systemic and cavernosal NO (Po0.0001 for both) and systemic GH levels (Po0.05) were declined compared to psychogenic. Systemic NO was positively correlated with GH in psychogenic (r ¼ 0.616, Po0.05), diabetic (r ¼ 0.583, Po0.05) and nondiabetic (r ¼ 0.615, Po0.05) patients and correlated positively with cGMP (r ¼ 0.605, Po0.05) but negatively with ACE activities (r ¼ À0.585, Po0.05) in diabetic patients. In conclusion, plasma levels of ET-1, ACE activities are elevated and associated with reduction of GH, NO and cGMP levels in the systemic and cavernous blood of ED patients. This disturbance may indicate endothelial dysfunction that may hind at their significance in the pathophysiology of ED.
Introduction
Erectile dysfunction (ED) is defined by the National Institutes of Health as the inability to attain or maintain an erection sufficient for satisfactory sexual performance. 1 It is a highly prevalent and often undertreated condition. Although a wide range of risk factors contributes to the development of ED, vasculogenic ED is recognized as the most common organic etiology (70%), about (30%) of it related to diabetes mellitus. 2 Psychogenic causes (30%) include depression, performance anxiety, relationship problems and psychosocial stressors. Combination of organic and psychogenic factors is common. 3 The cellular and molecular events involved in the regulation of penile tissue vascularity are not known. Advances in basic and clinical research will provide further interesting information about the pathophysiology of this common condition and hence provide future new therapeutic molecular targets. Nitric oxide (NO) is the principle mediator of penile erection which is released by nonadrenergic noncholinergic (NANC) neurons and corpora cavernosa endothelium. 4 It acts both as neurotransmitter in NANC nerve terminals of the penis and as vasodilator of the smooth muscle of penile arteries, sinusoids and trabeculae. Upon sexual arousal, neuronal impulses cause the release of NO from the neurons and endothelial cells of the corpus cavernosum, which leads to increases of cGMP formation. The latter induced relaxation of vascular and cavernosal smooth muscle. This permits engorgement of cavernosal sinusoids with blood and development of erection. 5 Alteration of the biology of NO accounts for various forms of erectile dysfunction. 6 Endothelin-1 (ET-1) is synthesized by endothelial cells lining sinusoids of the cavernous tissue and by smooth muscles. It is a potent vasoconstrictor peptide and paracrine factor in the regulation of muscle tone (maintenance of flaccidity). 7 One of particular interest in corporal physiology is the ability of subthreshold concentrations of endothelin to potentiate contractile responses to several vasospastic agents in diverse vascular tissue. 8 Angiotensin-converting enzyme (ACE) regulates the plasma level and different mechanisms of action of angiotensin II (Ang II) (potent vasoconstrictor) and kinins (potent vasodilators). It has the ability to degrade kinins and converts angiotensin I into Ang II. It is known that bradykinin induces the release of NO from the endothelial cells or the release of neuropeptide, such as calcitonin peptide, substance P and vasoactive intestinal polypeptide, from peripheral nerve terminals, thus leading to the relaxation of blood vessels and cavernous smooth muscle vasculature. 9 It has been shown that the human corpus cavernosum produces and secretes physiologically relevant amounts of Ang II, and Ang II receptors have been characterized in the mammalian cavernous compartment. The intracavernosal injection of Ang II has been reported to terminate penile erection in anesthetized dogs, and the application of an Ang II receptor antagonist resulted in penile erection. 10 Ang II induces vascular smooth muscle contraction through increasing cytosolic calcium 11 and also it facilitates the secretion of ET-1. 12 Growth hormone (GH) influences the growth and activity of different tissues. It influences the synthesis of insulin-like growth factor I (IGF-1). The latter is supposed to be the main mediator of GH action. 13 It has been found that GH and IGF-1 have roles in penile erection. Recent studies demonstrated that the level of GH in systemic and cavernous blood increases during penile tumescence. It stimulates the production of cGMP in cavernous tissue. 14 In view of this background, the aim of our study was to clarify the role of vasoactive mediators in ED. So, the plasma levels of NO, cGMP, ET-1, ACE and GH were determined during flaccid penile condition in the cavernous and systemic blood of men with psychogenic and organogenic erectile dysfunction. Owing to the fundamental role of NO in penile erection and its complex cascades with other measured vasoactive mediators, the correlation between NO and the other measured bioindices was evaluated.
Patients and methods

Patients and protocol
In all, 36 patients with mean age7s.d. (39.0879.07 y) with confirmed erectile dysfunction and 12 healthy potent adult men of matched age (36.5077.38 y) serving as controls were enrolled into the study after they provided written informed consent and this was approved by the local Medical Ethics Committee. The criteria for inclusion required that men are above 18 y old, engaged in a stable, monogamous heterosexual relationship and had a documented clinical diagnosis of ED for at least 6 months as evaluated by their physician. Exclusion criteria included genital anomalies, radical prostatectomy, an uncontrolled major medical illness or psychiatric condition or evidence of dementia within 6 months before the study onset. Patients were also excluded if they were currently or recently treated for their ED with intracorporeal injection or application of vasoactive drugs; a history of alcoholism or substance dependence or of smoking more than eight cigarettes/day.
A detailed medical and sexual history, complete physical examination including genital, and neurological examination (bulbocavernosal reflex to test integrity of the sacral arc, F and H waves latency from both lower limbs and somatosensory-evoked potential) were investigated. Serum biochemical and hormonal profiles were obtained from all participants before entry into the study including urine analysis, blood glucose, complete blood count, kidney and liver functions, testosterone, prolactin and thyroxin.
Each individual completed the International Index of Erectile Function (IIEF) questionnaire and the status of erectile function was proved by assessing responses on the 'erectile function domain' (EF), a score of EF 26-30 indicated no ED and a score of r25 identified ED. 15 To further characterize ED, an in office intracavernosal injection (ICI) testing using 10-20 mg of prostaglandin E 1 (PGE 1 ) and pharmaco-duplex Doppler ultrasonographic examination of the corpora cavernosa were done. Based on the results of the test, patients were classified into psychogenic and organogenic ED. The vascular diagnosis of organogenic ED patients was done using dynamic perfusion cavernosometry Vasoactive mediators and erectile dsyfunction E A Hamed et al based on previously published guidelines. 16 Arterial insufficiency was diagnosed when cavernous artery occlusion pressure was greater than 30 mmHg. Venous leakage was diagnosed when the flow-tomaintain value was greater than 3 ml/min and/or the pressure decay was greater than 45 mmHg. Patients were excluded from analysis when they failed to complete dynamic infusion cavernosometry or delayed postprocedure erection developed despite persistently abnormal veno-occlusive parameters during dynamic infusion cavernosometry. The latter situation indicated incomplete corporeal smooth muscle relaxation during the study, thus, negating the recorded veno-occlusive data. 17 The patients were subdivided into two main groups psychogenic and organogenic according to main underlying cause of ED and based on the diagnostic findings. Psychogenic patients (n ¼ 12; mean age7s.d., 36.9278.23 y; duration, 8.8272.41 months) were characterized by abnormal findings in the psychosexual evaluation and had no signs of neurologic disease, no abnormal testosterone levels, and no pathologic duplex sonography findings after injection of PGE 1 . The organogenic patients were further subdivided according to the underlying cause of ED into organogenic diabetic (n ¼ 12; 39.7278.15 y; 19.6779.72 months) and organogenic nondiabetic (n ¼ 12; 40.58710.93 y; 15.5878.94 months) patients. The organogenic diabetic ED patients were from type II diabetes, who had no event of neuropathies proven by normal bulbocavernous reflex, F and H waves latency from both lower limbs and somatosensory-evoked potential. These patients were treated with oral hypoglycemic drug. The concomitant diseases with organogenic nondiabetic ED were cardiac insufficient (n ¼ 6) hypertension (n ¼ 3) and respiratory dysfunction (n ¼ 3). Among the organogenic ED patients and based on dynamic cavernosometry results, 12 patients were diagnosed as venogenic, eight as arteriogenic and four as mixed venogenic and arteriogenic ED.
Blood sampling
Sufficient (3-5 ml) cavernosal and cubital venous blood sampling were taken from all the ED patients. Owing to the invasive nature of the procedure, no cavernosal blood samples were obtained from the normal control subjects. The participants were placed in supine position with the upper part of the body upright at approximately 301 and blood was withdrawn from a cubital vein and the cavernosal body simultaneously, as comprehensively described previously. 18 With respect to the circadian rhythm of GH, all blood withdrawals began at approximately 3:30. Blood samples were drawn into heparinized tubes treated with 10 mg/ml of aprotinin [500 kallikrein-inhibiting units (KIU)/ ml of blood, Sigma Aldrich, Poole, Dorset, UK] to prevent degradation of ET-1 and immediately placed on ice and then centrifuged at 41C, 3000 rpm for 10 min. The plasma was separated, aliquoted and stored at À701C until biochemical analyses.
Biochemical analysis
ET-1 levels were measured using enzyme-linked immunosorbent assay (ELISA) kit supplied by Assay Designs, Inc., Ann Arbor, MI 48105 (Cat.#90020, USA) according to the manufacturer's protocol. The lower detection limit of the kit was 0.14 pg/ml and the intra-assay and interassay coefficients of variations were 2.9 and 3.3%, respectively. GH levels were measured using a sandwich ELISA assay according to the manufacturer's instructions supplied by DiaMed Eurogen (Cat. # 730801, Turnhout, Belgium). The lower detection limit of the assay was o0.2 ng/ml and intraassay and interassay variations were 5.54 and 14.02%, respectively. Plasma level ACE activities were determined by using furylacrylyl phenylalanyl glycylglycine (FAPGG) as substrate as described previously. 19 NO levels were measured as total nitrite concentration after reduction of nitrate to nitrite according to the method described by van Bezooijen et al. 20 Plasma cGMP levels were measured using an immunoradiometric assay kit supplied by IBL GmbH (Cat. #29071/75, Flughafenstrasse, Hamburg, Germany) according to the manufacturer's protocol.
Statistical analysis
Data were analyzed using Prism software version 3. 21 All data were expressed as mean7s.d., unless otherwise indicated. Student's t-test (paired or unpaired as appropriated) was used for statistical comparison. Pearson correlation coefficient between NO and the measured biochemical indices were evaluated by the statistical significance of their linear regression using the total study samples. A P-value less than 0.05 was considered statistically significant.
Results
Plasma level of ET-1, GH, ACE, NO and cGMP in systemic and cavernosal blood of unselected patients with erectile dysfunction and healthy controls ( Figure 1) Plasma levels ET-1 and ACE activities were significantly increased (Po0.0001 and o0.01, respectively); while GH, NO and cGMP levels were Plasma levels of ET-1, GH, ACE, NO and cGMP in systemic and cavernosal blood of patients with psychogenic, diabetic and nondiabetic ED (Table 1) In comparison with controls, systemic plasma levels of ET-1 were significantly elevated in diabetic and nondiabetic ED (Po0.0001 for both) and ACE activity was significantly elevated in psychogenic, diabetic and nondiabetic ED patients (Po0.05, o0.01, o0.05, respectively). Nonsignificant differences were found between systemic and its corresponding cavernosal plasma levels of ET-1 and ACE activity activities in psychogenic, diabetic and nondiabetic patients. Diabetic and non-diabetic ED patients showed significantly higher ET-1 levels in both systemic and cavernosal blood (Po0.0001 for all) while, ACE showed only significant elevation of cavernosal level in diabetic (Po0.05) compared to psychogenic patients. Nonsignificant differences were found in systemic and cavernosal levels of all the studied bioindices when diabetic and nondiabetic patients were compared. Systemic plasma levels of GH, NO and cGMP significantly declined in diabetic and nondiabetic Vasoactive mediators and erectile dsyfunction E A Hamed et al ED patients (GH, Po0.0001, o0.001; NO, Po0.0001, o0.0001; cGMP, Po0.01, o0.01, respectively) 1 compared to controls. A significant increase in the cavernosal level of GH (Po0.01) in diabetic patients was found compared to its corresponding systemic level. In comparison with psychogenic ED patients, GH levels were significantly declined in both systemic and cavernosal blood in diabetic patients (Po0.001 and o0.05) and declined only in systemic blood (Po0.05) of nondiabetic patients, while NO levels showed significant decline of systemic and cavernosal blood in diabetic and nondiabetic patients (Po0.0001, for all). Meanwhile, cGMP showed decline in systemic and cavernosal levels in diabetic and nondiabetic ED patients but not reached significant levels.
Correlation of NO in systemic blood versus other studied bioindices in all subgroups (Table 2)
Systemic plasma level of NO was significantly positively correlated with systemic levels of GH in psychogenic (r ¼ 0.616, Po0.05), diabetic (r ¼ 0.583, Po0.05) and nondiabetic (r ¼ 0.615, Po0.05) ED patients. In addition, NO level was positively correlated with cGMP (r ¼ 0.605, Po0.05) but negatively correlated with ACE (r ¼ À0.585, Po0.05) in diabetic patients. Nonsignificant correlation between NO level and other studied bioindices was shown in cavernosal blood of psychogenic, diabetic and nondiabetic ED patients (data not shown).
Discussion
Penile erection is a hemodynamic process involving increased arterial inflow and restricted venous outflow from the penis, coordinated with the corpus cavernosus smooth muscle relaxation. 22 The process is under complex regulatory control by adrenergic, cholinergic and noradrenergic noncholinergic systems. However, biochemical substances locally released from the endothelial or smooth muscle components of the erectile tissue may also cooperate in this function. 6 Endothelial cells produce Ang II, ET-1, prostaglandin and NO. 
Po0.095 (NS)
Data are expressed as mean7s.d. NS=nonsignificant; ED=erectile dysfunction, *P: significance versus venous plasma of controls. **P: significance versus psychogenic erectile dysfunction.
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Imbalance of different endogenous neurotransmitters, neuromodulators and hormones colocalized to the corporal milieu has been reported as a principal mechanism of erectile dysfunction. 22 The presence of chronic illness such as heart disease, hypertension, diabetes mellitus and depression was considered as risk factors for ED. 3 Diabetes affects the cavernous nerve terminals and endothelial cells, resulting in deficiency of neurotransmitters and other locally produced vasoactive substances. 23 In the present study, we excluded patients with chronic alcohol intake or cigarette smoking more than eight cigarettes per day as they induced erectile dysfunction and some of the measured parameters affected by them (NO and ET-1). 24, 25 NO is considered as a principal mediator of erectile function adhering to signal transudation mechanisms in which guanylate cyclase is activated to produce cGMP, an effector of corporal smooth muscle relaxation. 16 Potential sources of NO in the penis include neurons, sinusoidal epithelium and corporal smooth muscle cells and alteration in its biology account for various forms of erectile dysfunction. 6 In this study, the vasoactive mediators were not measured in the cavernosal blood of healthy controls due to the invasive nature of the procedure. Systemic levels of NO were significantly decreased in both organogenic ED subgroups, diabetic and nondiabetic patients, compared to controls and psychogenic ED men and its cavernosal levels were significantly lower in diabetic and nondiabetic men compared to psychogenic ED men. Consistent with our results, Abdel-Fadeil et al 26 found significant lower systemic NO levels in organogenic ED patients than controls. Impairment of cavernous neurogenic and endothelium-dependent relaxation was recorded in diabetic patients with impotence. 27 Vasculogenic diseases particularly diabetes mellitus were reported to alter the synthesis of vasoactive compounds such as NO, prostacyclin (PGI 2 ) and ET-1. 5, 28 In this respect, Diamon et al 29 found significantly lower NO level in diabetic patients than healthy controls. Maejima et al 30 attributed the decreased vascular response in diabetic subjects to the diabetes-related abnormalities in the NO/cGMP pathway located at the subendothelial space, leading to impairment of action or inactivation of NO.
In the present study, a significant decrease in systemic plasma levels of cGMP in organogenic ED subgroups of patients compared to controls was observed. In addition, a significant positive correlation was found between systemic NO and cGMP in diabetic ED patients. This positive correlation could be explained by the fact that the relaxation of cavernous arterial and trabecular smooth muscle is dependent upon the stimulation of guanylyl cyclase activity by NO, and the subsequent accumulation of cGMP in the intracellular space. 18 cGMP activates its specific protein kinases which phosphorylate certain proteins to cause opening of potassium channels, closing of calcium channels and sequestration of intracellular calcium by endoplasmic reticulum. The resultant fall in intracellular calcium leads to smooth-muscle relaxation. Since the NO/cGMP pathway is crucial for penile erection, alteration of the level of cGMP and NO is a positive indicator of erectile impairment and hence many efforts have been done in order to enhance this pathway as a therapeutic approach for the treatment of erectile dysfunction. 31 The therapeutic action of phosphodiesterase-V inhibitors involves blocking the degradation of cGMP leading to enhanced relaxation of the corpus cavernosum smooth muscle. This molecular mechanism has proven sufficient to restore good erectile function to impotent men. 32 Becker et al 18 reported that the basal levels of cGMP in the blood flushing the lacunar spaces of the cavernous body in the state of developing erection might conceal a local release of cGMP that may occur within the penile erectile tissue. So, the quantitation of the cGMP is of no use in the evaluation of the physiologic mechanisms of penile erection in vivo and hence the concomitant recording of the levels of both NO and cGMP is more valuable. It has been suggested that GH is involved in sexual maturation and plays a regulatory role in male reproductive function. Deficiency may result in fatigability, loss of sexual desire and erection, oligospermia or azoospermia. It also plays an important role in the maintenance of penile erec- Vasoactive mediators and erectile dsyfunction E A Hamed et al tion, perhaps by augmentation of androgenic action, the preservation of endothelial NO synthase protein expression, and through a stimulating effect on cGMP generation in human cavernous smooth muscle. 33 Our study found significant decreases in systemic GH levels in diabetic and nondiabetic ED patients compared to controls. In diabetics, cavernosal GH level significantly declined versus its corresponding systemic levels and also versus the cavernosal levels in psychogenic ED patients. Similarly, Becker et al 33 found greater decline in systemic GH in all ED patients to about sevenfold than those registered in healthy men during penile flaccidity. The systemic level of GH was significantly positively correlated with systemic NO level in our organogenic subgroups and also psychogenic ED patients. In this respect, Becker et al 33 supposed that the biologic effects of GH might be mediated by IGF-I-stimulated endothelial NO formation. Physiologic concentrations of GH elevated intracellular cGMP levels in isolated human cavernous smooth muscle strips have also been demonstrated. 14 In the present study, cavernosal levels of ET-1 were not measured in healthy men due to the invasive technique of the procedure, so it is questionable whether levels of ET-1 reported in cavernous body blood of patients with ED were more elevated than in normal men. Previous studies 34, 35 reported the absence of any differences between venous and cavernosal levels of ET-1. In our subgroups of organogenic ED men, systemic ET-1 levels were significantly higher than controls and psychogenic patients and also, its cavernosal levels were significantly higher compared to psychogenic ED patients. Similarly, Francavilla et al 34 found significant increase in systemic ET-1 level in patients with diabetic and nondiabetic ED compared with controls. The authors concluded that elevated plasma level of ET-1 in peripheral versus blood was indicative of endothelial dysfunction that might contribute to erectile failure. Recently, Abdel-Fadeil et al 26 found that ET-1 levels were significantly higher in organogenic compared to psychogenic ED patients (systemic and cavernosal levels) and controls (systemic levels). The ET-1 upregulation could represent a pathophysiological pathway in diabetic ED or compensatory response to the impaired NO /PGI 2 release which has been reported in diabetic animal models and humans. 35 In this concept, Kadioglu et al 36 reported decline in cavernosal NO levels and elevation of ET-1 levels in arteriogenic ED patients and this may be due to cavernosal damage. In agreement with us, Rossi et al 35 reported no change in ET-1 levels in psychogenic ED patients. Our results failed to show any correlation between NO and ET-1. Contrarily, Abdel-Fadeil et al 26 found significant negative correlation between NO and ET-1 in either systemic or cavernosal blood of ED patients.
It is well known that ACE activity regulates the plasma levels of Ang II. 37 In cultured endothelial cells, Ang II may increase the release of ET-1. 38 In the present study, significant increased systemic venous levels of ACE activities were found in psychogenic and organogenic ED subgroups compared to controls. In addition, the cavernosal level of ACE activity was significantly higher in diabetic compared to psychogenic ED patients. Systemic blood ACE activity was negatively correlated with NO level in our diabetic ED patients. In this respect, Becker et al 22 reported that human corpus cavernosum is an Ang II producing the paracrine system. Ang II regulates the expression of NO synthase and NO production, whereas NO downregulates the Ang II type I receptors. The interaction between Ang II and NO occurs in both the endothelial and vascular smooth muscle cells. Vascular smooth muscle constricts in response to Ang II and dilates in response to NO. A feedback mechanism between Ang II and NO is critical for normal vascular structure and function. Many vascular diseases are associated with imbalance of Ang II and NO actions. 37 Park et al 39 reported that the deletion of polymorphism in the ACE gene, the DD genotype, as a marker of general vascular disease, may be seen more frequently in men with a diagnosis of vasculogenic erectile dysfunction. It has been suggested that ACE inhibitors might be used in the treatment of vasculogenic ED. 22 
Conclusions
This study showed the disturbances in systemic and cavernosal levels of vasoactive mediators particularly in organogenic ED patients. The significant increase in systemic levels of ET-1 and ACE were associated with reduction in the systemic levels of GH, NO and cGMP in both diabetic and nondiabetic ED patients. These disturbances indicate endothelial dysfunction and imbalance between these vasoactive mediators, which might contribute to erectile dysfunction. The psychogenic ED patients show significant elevation in systemic ACE activity compared to controls. However, further studies are needed to elucidate the pathogenesis of psychogenic ED. Positive correlation between NO and each of GH and cGMP and its negative correlation with ACE activity indicated the complex role of NO in erectile dysfunction. There might be a rationale for the use of inhibitors for ACE, ET-1 and phosphodiesterase-V in the treatment of ED and for future molecular therapeutic targets.
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